Lessons from a $70.6M Medicare Fraud Case in Diagnostics

A $70.6 million Medicare fraud case marks a criminal reckoning for a mobile diagnostics company — and the lessons go far beyond one set of defendants.

In February 2026, federal prosecutors in Boston marked the culmination of the criminal proceedings against several key defendants in a years-long conspiracy to defraud Medicare through medically unnecessary brain scans. The case involves a mobile diagnostics company, a web of sham contracts, cash payments to physicians, and — when all the numbers are added up — approximately $27.2 million in Medicare payments for fraudulent claims. For healthcare providers across the country, the details of this case deserve more than a passing glance at a DOJ press release. They deserve careful, honest reflection.

What Actually Happened

From at least June 2013 to at least September 2020, a mobile medical diagnostics company and several other stakeholders conspired to order medically unnecessary transcranial doppler (TCD) scans. TCD scans are typically used to screen patients for stroke or monitor other vascular concerns. In this case, however, doctors were paid kickbacks — some in cash, some by check — to order scans without medical necessity, for patients who had not been documented as requiring them.

The concealment mechanism is what makes this case particularly instructive. Sham rental and administrative service agreements were created to make it appear on paper as if the doctors were being paid for legitimate reasons. These arrangements were structured to mimic fair-market-value compensation for space and administrative resources — but in economic reality they functioned as per-test payments.

The financial scale was significant. Medicare ultimately paid $27.2 million to the TCD provider for these claims, against fraudulent billings of approximately $70.6 million.

Multiple individuals were sentenced. Timothy Doyle, 45, of Selden, N.Y., was sentenced to 14 months in prison, followed by one year of supervised release, and ordered to pay $27,225,434 in restitution and $1,102,725 in forfeiture. Co-defendant David Fuhrmann received a harsher sentence. Fuhrmann was sentenced to three years in prison, followed by one year of supervised release, and ordered to pay $27,225,434 in restitution, forfeit $1,102,725, and pay a $30,000 fine. It is worth noting that restitution figures of this scale are typically imposed on a joint and several basis — meaning each defendant is individually liable for the full amount, not merely a proportional share. A third defendant received eight months. The criminal cases against these defendants have concluded, though related civil False Claims Act proceedings and investigations of additional participants may remain ongoing.

Physicians were not merely passive recipients. One ophthalmologist in Connecticut conspired with a diagnostics company principal to order hundreds of medically unnecessary TCD scans in exchange for cash kickbacks of $100 to $125 per test, using false patient diagnoses to support the orders. The scheme resulted in fraudulent bills of over $3 million to Medicare and private insurers.

This Is Not an Isolated Case — It Is a Pattern

What makes the federal enforcement trajectory significant is not the Massachusetts sentencings alone, but the accumulation of similar allegations across multiple jurisdictions and specialties. Similar allegations involving TCD billing and kickback arrangements have appeared in multiple states — across ophthalmology, neurology, and primary care — involving separate third-party testing companies.

In January 2026, five Florida ophthalmology practices agreed to pay a total of nearly $6 million to resolve alleged violations of the False Claims Act arising from their billing for transcranial doppler ultrasounds through a kickback arrangement with a third-party testing company. All five practices agreed to cooperate with the Justice Department’s ongoing investigations of other participants in the alleged scheme.

That last sentence — cooperating with ongoing investigations — is not standard language. It signals that prosecutors view these settlements as steppingstones toward additional enforcement actions, not endpoints.

The DOJ has been explicit about intent. Assistant Attorney General Brett A. Shumate stated that kickbacks and false claims increase healthcare costs for all Americans and undermine the integrity of healthcare decision-making, and that combating such schemes will remain a priority for the Justice Department.

Earlier, in November 2024, an ophthalmology practice in West Central Florida entered into an approximately $1.3 million settlement to resolve kickback allegations arising from its billing for TCD ultrasounds, involving a contractual arrangement with a third-party vendor of turnkey mobile TCD services whereby even before receiving the TCD result, the practice and the vendor identified the patient as having received a serious diagnosis that could qualify the patient for Medicare or Medicaid reimbursement.

The HHS Office of Inspector General has previously found similar “contractual joint ventures” among healthcare providers and third-party vendors to be problematic — arrangements that generally involve a healthcare provider contracting with an outside company to provide almost all aspects of a service while the provider bills for it.

The Paper Trail Illusion

One of the most important compliance lessons from this case involves the false security of documentation. Providers and administrators sometimes assume that the existence of a signed agreement — a space rental contract, an administrative services arrangement, a fair-market-value attestation — provides legal cover. The TCD cases dismantle that assumption completely.

Prosecutors demonstrated repeatedly that the settling practices submitted, or caused the submission of, false claims premised on false diagnoses and resulting from violations of the Anti-Kickback Statute and the Stark Law, even where formal contracts existed between the parties. Having paperwork is not the same as having a legitimate arrangement. What matters is the economic reality underneath.

The Anti-Kickback Statute does not ask whether a contract exists. It asks whether any part of the compensation arrangement was intended to induce referrals. If payment tracks referral volume — regardless of what the contract calls it — the paper above it is insufficient protection.

What Providers Must Pay Attention to Now

Audit every vendor relationship involving mobile diagnostic services. If a third-party company is offering mobile diagnostic services — TCD scans, cardiac monitoring, sleep studies, genetic testing — and has proposed any arrangement involving payments back to your practice or its physicians, that arrangement needs immediate legal review. The key question: does compensation vary in any way with the number of tests ordered or referred? If the answer is yes, the structure raises serious AKS risk regardless of how the payments are labeled.

“Fair market value” is not a magic phrase. The use of fair-market-value language in a contract does not, by itself, create a safe harbor. In every TCD case above, the arrangements were structured to pay per test and concealed behind FMV language. True FMV assessments must be grounded in independent, contemporaneous documentation — not post-hoc justifications prepared after a government inquiry has begun.

Understand what your physicians are signing. Physicians who signed orders in these schemes did not all fully grasp the individual legal exposure they were accepting. Ordering physicians bear personal criminal and civil liability. Institutional compliance programs need to reach individual clinicians — not just billing staff and administrators.

A vendor’s documentation does not protect you. As the Holland & Knight analysis of the Florida TCD settlements noted, the DOJ has a deep arsenal of federal and Florida laws to protect the integrity of Medicare and Medicaid programs and ensure that providers do not misappropriate government funding. When a vendor provides “turnkey” services and handles most of the operational risk while you bill and refer, regulators scrutinize whether the provider is a genuine participant in the service or merely a conduit for billing.

Whistleblower exposure is real and growing. The civil settlements in the Florida cases resolved claims in a lawsuit filed under the qui tam or whistleblower provision of the False Claims Act, which permits private parties to file suit on behalf of the United States for false claims. Any kickback arrangement involving multiple parties has multiple potential whistleblowers. Compliance programs should be designed assuming that any participant could go to federal authorities.

The Enforcement Signal

This cluster of cases — sentencings in Boston, civil settlements in Florida, guilty pleas in Connecticut — did not emerge from a single investigation. It reflects a sustained multi-agency enforcement priority. The DOJ, HHS-OIG, the FBI, the IRS Criminal Investigation division, and the U.S. Postal Inspection Service were all involved in the Massachusetts criminal proceedings alone. That level of coordination does not get assembled for one-off matters.

The enforcement timeline is also instructive. The Massachusetts scheme ran from 2013 to 2020. Sentencings completed in early 2026. That is a decade from inception to conclusion — meaning arrangements entered into today may not face legal consequences until the mid-2030s, but they will face consequences.

For providers navigating a landscape of mobile diagnostic vendors, third-party testing arrangements, and complex referral structures, this body of cases sends a consistent message: the arrangement that looks like a revenue opportunity today may look like a federal indictment several years from now. The time to scrutinize those agreements is now, not after a subpoena arrives.

Sources